Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""ACTIVIN"" wg kryterium: Temat


Tytuł:
Polypeptide Substrate Accessibility Hypothesis: Gain-of-Function R206H Mutation Allosterically Affects Activin Receptor-like Protein Kinase Activity.
Autorzy:
Groppe JC; Department of Biomedical Sciences, Texas A&M University College of Dentistry, 3302 Gaston Ave, Dallas, TX 75246, USA.
Lu G; Department of Biomedical Sciences, Texas A&M University College of Dentistry, 3302 Gaston Ave, Dallas, TX 75246, USA.
Tandang-Silvas MR; Department of Biomedical Sciences, Texas A&M University College of Dentistry, 3302 Gaston Ave, Dallas, TX 75246, USA.
Pathi A; Department of Biomedical Sciences, Texas A&M University College of Dentistry, 3302 Gaston Ave, Dallas, TX 75246, USA.
Konda S; Department of Biomedical Sciences, Texas A&M University College of Dentistry, 3302 Gaston Ave, Dallas, TX 75246, USA.
Wu J; Department of Biomedical Sciences, Texas A&M University College of Dentistry, 3302 Gaston Ave, Dallas, TX 75246, USA.
Le VQ; Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA.; Program in Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Culbert AL; Department of Orthopaedics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Shore EM; Department of Orthopaedics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Wharton KA; Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA.
Kaplan FS; Department of Orthopaedics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2023 Jul 14; Vol. 13 (7). Date of Electronic Publication: 2023 Jul 14.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Gain of Function Mutation*
Activin Receptors, Type I*/genetics
Activin Receptors, Type I*/metabolism
Animals ; Mice ; Activin Receptors/genetics ; Fibroblasts/metabolism ; Mutation ; Peptides/genetics
Czasopismo naukowe
Tytuł:
AAV-Mediated Targeting of the Activin A-ACVR1 Signaling in Fibrodysplasia Ossificans Progressiva.
Autorzy:
Yang YS; Department of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Lin C; Department of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Ma H; Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.; Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.; Viral Vector Core, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Xie J; Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.; Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.; Viral Vector Core, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Kaplan FS; Department of Orthopaedic Surgery, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.; Department of Medicine, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.; The Center for Research in FOP and Related Disorders, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Gao G; Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.; Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.; Viral Vector Core, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.; Li Weibo Institute for Rare Diseases Research, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Shim JH; Department of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.; Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.; Li Weibo Institute for Rare Diseases Research, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2023 Sep 08; Vol. 13 (9). Date of Electronic Publication: 2023 Sep 08.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Activin Receptors, Type I*/genetics
Myositis Ossificans*/genetics
Myositis Ossificans*/therapy
Animals ; Humans ; Mice ; Activins ; Dependovirus/genetics ; Osteogenesis
Czasopismo naukowe
Tytuł:
The Activation of the Fibrodysplasia Ossificans Progressiva-Inducing ALK2-R206H Mutant Depends on the Distinct Homo-Oligomerization Patterns of ACVR2B and ACVR2A.
Autorzy:
Szilágyi SS; Department of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
Burdzinski W; Institute for Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany.; Berlin-Brandenburg School for Regenerative Therapies (BSRT), Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
Jatzlau J; Institute for Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany.
Ehrlich M; Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
Knaus P; Institute for Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany.
Henis YI; Department of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
Pokaż więcej
Źródło:
Cells [Cells] 2024 Jan 25; Vol. 13 (3). Date of Electronic Publication: 2024 Jan 25.
Typ publikacji:
Journal Article
MeSH Terms:
Myositis Ossificans*/genetics
Humans ; Ligands ; Mutation/genetics ; Activins ; Signal Transduction/physiology ; Activin Receptors, Type II/genetics
Czasopismo naukowe
Tytuł:
iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
Autorzy:
Gao P; State Key Laboratory of Oral Diseases and National Center for Stomatology and National Clinical Research Center for Oral Diseases and, Department of General Dentistry, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, Sichuan, China.; Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Inada Y; Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Hotta A; Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Sakurai H; Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Ikeya M; Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. .
Pokaż więcej
Źródło:
Stem cell research & therapy [Stem Cell Res Ther] 2024 Mar 18; Vol. 15 (1), pp. 83. Date of Electronic Publication: 2024 Mar 18.
Typ publikacji:
Journal Article
MeSH Terms:
Myositis Ossificans*/genetics
Myositis Ossificans*/therapy
Ossification, Heterotopic*/therapy
Ossification, Heterotopic*/genetics
Female ; Humans ; Mice ; Animals ; Bone Morphogenetic Proteins/genetics ; Bone Morphogenetic Proteins/metabolism ; Bone Morphogenetic Proteins/pharmacology ; Signal Transduction ; Mice, Transgenic ; Mutation ; Activin Receptors, Type II/genetics ; Activin Receptors, Type II/metabolism ; Activin Receptors, Type II/pharmacology
Czasopismo naukowe
Tytuł:
FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells.
Autorzy:
Quist-Løkken I; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim, Norway.
Andersson-Rusch C; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim, Norway.
Kastnes MH; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim, Norway.; Centre of Molecular Inflammation Research, Norwegian University of Science and Technology - NTNU, Trondheim, Norway.
Kolos JM; Department of Chemistry, Technical University of Darmstadt, Darmstadt, Germany.
Jatzlau J; Institute for Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Hella H; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim, Norway.
Olsen OE; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim, Norway.
Sundan A; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim, Norway.; Centre of Molecular Inflammation Research, Norwegian University of Science and Technology - NTNU, Trondheim, Norway.; Department of Hematology, St. Olav's University Hospital, Trondheim, Norway.
Knaus P; Institute for Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Hausch F; Department of Chemistry, Technical University of Darmstadt, Darmstadt, Germany.
Holien T; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim, Norway. .; Department of Immunology and Transfusion Medicine, St. Olav's University Hospital, Trondheim, Norway. .; Department of Hematology, St. Olav's University Hospital, Trondheim, Norway. .; Department of Biomedical Laboratory Science, Norwegian University of Science and Technology - NTNU, Trondheim, Norway. .
Pokaż więcej
Źródło:
Cell communication and signaling : CCS [Cell Commun Signal] 2023 Jan 30; Vol. 21 (1), pp. 25. Date of Electronic Publication: 2023 Jan 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Video-Audio Media
MeSH Terms:
Multiple Myeloma*
Tacrolimus Binding Protein 1A*/metabolism
Activin Receptors, Type I*/metabolism
Humans ; Bone Morphogenetic Proteins/metabolism ; RNA, Small Interfering ; Tacrolimus/pharmacology
Czasopismo naukowe
Tytuł:
Luspatercept, a two-edged sword in beta-thalassemia-associated paravertebral extramedullary hematopoietic masses (EHMs).
Autorzy:
Alashkar F; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Klump H; Institute of Transfusion Medicine, University Hospital Essen, Essen, Germany.
Lange CP; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Proske P; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Schüssler M; Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Yamamoto R; MVZ Dr. Eberhard & Partner Dortmund, Dortmund, Germany.
Carpinteiro A; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Institute for Molecular Biology, University of Duisburg-Essen, Essen, Germany.
Berliner CA; Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Schlosser TW; Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Röth A; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Reinhardt HC; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2022 Dec; Vol. 109 (6), pp. 664-671. Date of Electronic Publication: 2022 Sep 14.
Typ publikacji:
Journal Article
MeSH Terms:
Activin Receptors, Type II*/adverse effects
Activin Receptors, Type II*/therapeutic use
beta-Thalassemia*/complications
beta-Thalassemia*/diagnosis
beta-Thalassemia*/drug therapy
Adult ; Humans ; Immunoglobulin Fc Fragments/adverse effects ; Immunoglobulin Fc Fragments/therapeutic use ; Recombinant Fusion Proteins/adverse effects ; Recombinant Fusion Proteins/therapeutic use
Czasopismo naukowe
Tytuł:
Activin A Modulates Betaglycan Shedding via the ALK4-SMAD3-Dependent Pathway in Endometriotic Cells.
Autorzy:
Mwaura AN; Faculty of Medicine, Center of Gynecology and Obstetrics, Justus-Liebig-University, D-35392 Giessen, Germany.
Riaz MA; Faculty of Medicine, Center of Gynecology and Obstetrics, Justus-Liebig-University, D-35392 Giessen, Germany.
Maoga JB; Faculty of Medicine, Center of Gynecology and Obstetrics, Justus-Liebig-University, D-35392 Giessen, Germany.
Mecha E; Department of Biochemistry, University of Nairobi, Nairobi P.O. Box 30197-00100, Kenya.
Omwandho COA; Department of Biochemistry, University of Nairobi, Nairobi P.O. Box 30197-00100, Kenya.; Department of Health Sciences, Kirinyaga University, Kerugoya P.O. Box 143-10300, Kenya.
Scheiner-Bobis G; Institute for Veterinary Physiology and Biochemistry, School of Veterinary Medicine, Justus-Liebig-University, D-35392 Giessen, Germany.
Meinhold-Heerlein I; Faculty of Medicine, Center of Gynecology and Obstetrics, Justus-Liebig-University, D-35392 Giessen, Germany.
Konrad L; Faculty of Medicine, Center of Gynecology and Obstetrics, Justus-Liebig-University, D-35392 Giessen, Germany.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2022 Nov 24; Vol. 12 (12). Date of Electronic Publication: 2022 Nov 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Activins*/pharmacology
Activins*/metabolism
Endometriosis*/metabolism
Receptors, Transforming Growth Factor beta*/metabolism
Activin Receptors, Type I*
Female ; Humans ; Matrix Metalloproteinase 2/genetics ; Matrix Metalloproteinase 2/metabolism ; Matrix Metalloproteinase 3/genetics ; Matrix Metalloproteinase 3/metabolism ; Smad3 Protein/metabolism ; Transforming Growth Factor beta/metabolism
Czasopismo naukowe
Tytuł:
Recapitulation of pro-inflammatory signature of monocytes with ACVR1A mutation using FOP patient-derived iPSCs.
Autorzy:
Maekawa H; Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.; Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Jin Y; Department of Regeneration Sciences and Engineering, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Nishio M; Department of Regeneration Sciences and Engineering, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Kawai S; Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.; Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Nagata S; Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Kamakura T; Department of Regeneration Sciences and Engineering, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Yoshitomi H; Department of Regeneration Sciences and Engineering, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.; Department of Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Niwa A; Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Saito MK; Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Matsuda S; Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Toguchida J; Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan. .; Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. .; Department of Regeneration Sciences and Engineering, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan. .; Department of Fundamental Cell Technology, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan. .
Pokaż więcej
Źródło:
Orphanet journal of rare diseases [Orphanet J Rare Dis] 2022 Sep 21; Vol. 17 (1), pp. 364. Date of Electronic Publication: 2022 Sep 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Myositis Ossificans*/pathology
Ossification, Heterotopic*/genetics
Ossification, Heterotopic*/pathology
Activin Receptors, Type I/*genetics
Activin Receptors, Type I/metabolism ; Activins/genetics ; Activins/metabolism ; Animals ; Doxycycline ; Humans ; Inflammation/genetics ; Lipopolysaccharides ; Mice ; Monocytes/metabolism ; Monocytes/pathology ; Mutation/genetics ; Signal Transduction/genetics ; Transforming Growth Factor beta/genetics ; Transforming Growth Factor beta/metabolism
Czasopismo naukowe
Tytuł:
Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.
Autorzy:
Xie C; College of Veterinary Medicine, Western University of Health Sciences, Pomona, CA 91766, USA.
Jiang W; College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA.
Lacroix JJ; Graduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.
Luo Y; College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA.
Hao J; College of Veterinary Medicine, Western University of Health Sciences, Pomona, CA 91766, USA.; Graduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2020 Sep 05; Vol. 21 (18). Date of Electronic Publication: 2020 Sep 05.
Typ publikacji:
Journal Article
MeSH Terms:
Activin Receptors, Type I/*metabolism
Activins/*metabolism
Bone Morphogenetic Proteins/*metabolism
Activin Receptors, Type I/genetics ; Activin Receptors, Type II/genetics ; Activin Receptors, Type II/metabolism ; Activins/physiology ; Animals ; Bone Morphogenetic Protein Receptors, Type I/genetics ; Bone Morphogenetic Protein Receptors, Type II/genetics ; Bone Morphogenetic Proteins/physiology ; Cell Differentiation/physiology ; Cell Line ; Gene Expression Regulation/genetics ; HEK293 Cells ; Hep G2 Cells ; Humans ; Mice ; Ossification, Heterotopic/genetics ; Phosphorylation ; Signal Transduction/genetics ; Signal Transduction/physiology ; Transforming Growth Factor beta/metabolism
Czasopismo naukowe
Tytuł:
Activin type I receptor polymorphisms and body composition in older individuals with sarcopenia-Analyses from the LACE randomised controlled trial.
Autorzy:
Bashir T; Cardiovascular and Respiratory Interface Section, National Heart and Lung Institute, Imperial College London, South Kensington Campus, London, United Kingdom.
Achison M; Tayside Clinical Trials Unit (TCTU), Tayside Medical Science Centre (TASC), Ninewells Hospital & Medical School, University of Dundee, Dundee, United Kingdom.
Adamson S; Tayside Clinical Trials Unit (TCTU), Tayside Medical Science Centre (TASC), Ninewells Hospital & Medical School, University of Dundee, Dundee, United Kingdom.
Akpan A; Liverpool University Hospitals NHS FT Trust, Clinical Research Network Northwest Coast, University of Liverpool, Liverpool, United Kingdom.
Aspray T; AGE Research Group, NIHR Newcastle Biomedical Research Centre, Translational Clinical Research Institute, Cumbria Northumberland Tyne and Wear NHS Foundation Trust and Newcastle upon Tyne Hospitals NHS Trust, Newcastle University, Newcastle upon Tyne, United Kingdom.
Avenell A; Health Services Research Unit, University of Aberdeen, Aberdeen, United Kingdom.
Band MM; Tayside Clinical Trials Unit (TCTU), Tayside Medical Science Centre (TASC), Ninewells Hospital & Medical School, University of Dundee, Dundee, United Kingdom.
Burton LA; Medicine for the Elderly, NHS Tayside, Dundee, United Kingdom.; Ageing and Health, University of Dundee, Dundee, United Kingdom.
Cvoro V; Victoria Hospital, Kirkcaldy, United Kingdom.; Centre for Clinical Brain Sciences University of Edinburgh, Edinburgh, United Kingdom.
Donnan PT; Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, United Kingdom.
Duncan GW; Centre for Clinical Brain Sciences University of Edinburgh, Edinburgh, United Kingdom.; Medicine for the Elderly, NHS Lothian, Edinburgh, United Kingdom.
George J; Division of Molecular & Clinical Medicine, Dept Clinical Pharmacology, Ninewells Hospital, University of Dundee Medical School, Dundee, United Kingdom.
Gordon AL; Unit of Injury, Inflammation and Recovery, School of Medicine, University of Nottingham, Nottingham, United Kingdom.; NIHR Nottingham Biomedical Research Centre, Department of Medicine for the Elderly, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, United Kingdom.
Gregson CL; Musculoskeletal Research Unit, Bristol Medical School, University of Bristol, Bristol, United Kingdom.; Older Person's Unit, Royal United Hospital NHS Foundation Trust Bath, Combe Park, Bath, United Kingdom.
Hapca A; Tayside Clinical Trials Unit (TCTU), Tayside Medical Science Centre (TASC), Ninewells Hospital & Medical School, University of Dundee, Dundee, United Kingdom.
Hume C; Tayside Clinical Trials Unit (TCTU), Tayside Medical Science Centre (TASC), Ninewells Hospital & Medical School, University of Dundee, Dundee, United Kingdom.
Jackson TA; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.
Kerr S; Department of Older People's Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
Kilgour A; Medicine for the Elderly, NHS Lothian, Edinburgh, United Kingdom.; Ageing and Health Research Group, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
Masud T; Clinical Gerontology Research Unit, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, United Kingdom.
McKenzie A; Tayside Clinical Trials Unit (TCTU), Tayside Medical Science Centre (TASC), Ninewells Hospital & Medical School, University of Dundee, Dundee, United Kingdom.
McKenzie E; Tayside Clinical Trials Unit (TCTU), Tayside Medical Science Centre (TASC), Ninewells Hospital & Medical School, University of Dundee, Dundee, United Kingdom.
Patel H; NIHR Biomedical Research Centre, University of Southampton and University Hospital Southampton NHSFT, Southampton, United Kingdom.
Pilvinyte K; Tayside Clinical Trials Unit (TCTU), Tayside Medical Science Centre (TASC), Ninewells Hospital & Medical School, University of Dundee, Dundee, United Kingdom.
Roberts HC; Academic Geriatric Medicine, Mailpoint 807 Southampton General Hospital, University of Southampton, Southampton, United Kingdom.
Rossios C; Cardiovascular and Respiratory Interface Section, National Heart and Lung Institute, Imperial College London, South Kensington Campus, London, United Kingdom.
Sayer AA; AGE Research Group, NIHR Newcastle Biomedical Research Centre, Translational Clinical Research Institute, Cumbria Northumberland Tyne and Wear NHS Foundation Trust and Newcastle upon Tyne Hospitals NHS Trust, Newcastle University, Newcastle upon Tyne, United Kingdom.
Smith KT; Tayside Clinical Trials Unit (TCTU), Tayside Medical Science Centre (TASC), Ninewells Hospital & Medical School, University of Dundee, Dundee, United Kingdom.
Soiza RL; Ageing & Clinical Experimental Research (ACER) Group, University of Aberdeen, Aberdeen, United Kingdom.
Steves CJ; Department of Twin Research and Genetic Epidemiology, King's College London, Department of Clinical Gerontology, King's College Hospital, London, United Kingdom.
Struthers AD; Division of Molecular & Clinical Medicine, Dept Clinical Pharmacology, Ninewells Hospital, University of Dundee Medical School, Dundee, United Kingdom.
Tiwari D; Bournemouth University and Royal Bournemouth Hospital, Bournemouth, United Kingdom.
Whitney J; School of Population Health & Environmental Sciences, King's College London and King's College Hospital, London, United Kingdom.
Witham MD; AGE Research Group, NIHR Newcastle Biomedical Research Centre, Translational Clinical Research Institute, Cumbria Northumberland Tyne and Wear NHS Foundation Trust and Newcastle upon Tyne Hospitals NHS Trust, Newcastle University, Newcastle upon Tyne, United Kingdom.
Kemp PR; Cardiovascular and Respiratory Interface Section, National Heart and Lung Institute, Imperial College London, South Kensington Campus, London, United Kingdom.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Nov 14; Vol. 18 (11), pp. e0294330. Date of Electronic Publication: 2023 Nov 14 (Print Publication: 2023).
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Sarcopenia*/genetics
Male ; Female ; Humans ; Aged ; Myostatin ; Activin Receptors ; Cross-Sectional Studies ; Body Composition/genetics ; Activins/genetics ; Muscle, Skeletal
Czasopismo naukowe
Tytuł:
ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization.
Autorzy:
Lu X; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.; Key Laboratory of Tumor Immunology in Heilongjiang, Harbin, China.; China Clinical Research Center for Colorectal Cancer in Heilongjiang, Harbin, China.; Department of Orthopedic Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Liu R; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Liao Y; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Cui L; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Sun H; School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Zhang D; Department of Neurosurgery, Harbin Medical University Cancer Hospital, Harbin, China.
Wang B; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Fang L; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Guan X; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Yao Y; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. .; Key Laboratory of Tumor Immunology in Heilongjiang, Harbin, China. .; China Clinical Research Center for Colorectal Cancer in Heilongjiang, Harbin, China. .; Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China. .
Liu C; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. .; Key Laboratory of Tumor Immunology in Heilongjiang, Harbin, China. .; China Clinical Research Center for Colorectal Cancer in Heilongjiang, Harbin, China. .; Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China. .
Zhang Y; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. .; Key Laboratory of Tumor Immunology in Heilongjiang, Harbin, China. .; China Clinical Research Center for Colorectal Cancer in Heilongjiang, Harbin, China. .; Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China. .
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2023 Sep 25; Vol. 21 (1), pp. 366. Date of Electronic Publication: 2023 Sep 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
MicroRNAs*/metabolism
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/metabolism
Humans ; beta Catenin/genetics ; beta Catenin/metabolism ; beta Catenin/pharmacology ; Tyrosine Kinase Inhibitors ; Lysine/genetics ; Lysine/metabolism ; Lysine/pharmacology ; Glutathione Peroxidase/genetics ; Glutathione Peroxidase/metabolism ; Glutathione Peroxidase/pharmacology ; Cell Line, Tumor ; Cell Proliferation/genetics ; Gene Expression Regulation, Neoplastic ; Activin Receptors, Type II/genetics ; Activin Receptors, Type II/metabolism ; Activin Receptors, Type II/pharmacology ; Ubiquitin-Specific Proteases/genetics ; Ubiquitin-Specific Proteases/metabolism ; Ubiquitin-Specific Proteases/pharmacology
Czasopismo naukowe
Tytuł:
Hereditary hemorrhagic telangiectasia: First demonstration of a founder effect in Italy; the ACVRL1 c.289_294del variant originated in the country of Bergamo 200 years ago.
Autorzy:
Sbalchiero A; General Biology and Medical Genetics Unit, Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Abu Hweij Y; General Biology and Medical Genetics Unit, Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Mazza T; Laboratory of Bioinformatics, Fondazione IRCCS Casa Sollievo della Sofferenza-Mendel, San Giovanni Rotondo (FG), Italy.
Buscarini E; UOC of Gastroenterology-Reference Centre for HHT, ASST Ospedale Maggiore di Crema, Crema (CR), Italy.
Scotti C; Immunology and General Pathology Unit, Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Pagella F; UOC of Otorhinolaryngology, Department of Surgical Sciences, University of Pavia, Pavia, Italy.; UOC of Otorhinolaryngology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Manfredi G; UOC of Gastroenterology-Reference Centre for HHT, ASST Ospedale Maggiore di Crema, Crema (CR), Italy.
Matti E; UOC of Otorhinolaryngology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Spinozzi G; UOC of Otorhinolaryngology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Olivieri C; General Biology and Medical Genetics Unit, Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Pokaż więcej
Źródło:
Molecular genetics & genomic medicine [Mol Genet Genomic Med] 2022 Aug; Vol. 10 (8), pp. e1972. Date of Electronic Publication: 2022 May 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Activin Receptors, Type II*/genetics
Telangiectasia, Hereditary Hemorrhagic*/diagnosis
Endoglin/genetics ; Founder Effect ; Heterozygote ; Humans ; Italy ; Mutation
Czasopismo naukowe
Tytuł:
Characterization of Fibrodysplasia Ossificans Progessiva relevant Acvr1/Acvr2 Activin receptors in medaka (Oryzias latipes).
Autorzy:
Trumpp, Michael (AUTHOR)
Tan, Wen Hui (AUTHOR)
Burdzinski, Wiktor (AUTHOR)
Basler, Yara (AUTHOR)
Jatzlau, Jerome (AUTHOR)
Knaus, Petra (AUTHOR)
Winkler, Christoph (AUTHOR)
Pokaż więcej
Źródło:
PLoS ONE. 9/14/2023, Vol. 18 Issue 9, p1-24. 24p.
Czasopismo naukowe
Tytuł:
Blockade of Activin Receptor IIB Protects Arthritis Pathogenesis by Non‐Amplification of Activin A‐ACVR2B‐NOX4 Axis Pathway.
Autorzy:
Jeon, Jimin (AUTHOR)
Lee, Hyemi (AUTHOR)
Jeon, Min‐Seung (AUTHOR)
Kim, Seok‐Jung (AUTHOR)
Choi, Cham (AUTHOR)
Kim, Ki Woo (AUTHOR)
Yang, Dong Joo (AUTHOR)
Lee, Sangho (AUTHOR)
Bae, Yong‐Soo (AUTHOR)
Choi, Won Il (AUTHOR)
Jung, Juyeon (AUTHOR)
Eyun, Seong‐il (AUTHOR)
Yang, Siyoung (AUTHOR)
Pokaż więcej
Źródło:
Advanced Science. 5/17/2023, Vol. 10 Issue 14, p1-15. 15p.
Czasopismo naukowe
Tytuł:
The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva.
Autorzy:
Ye Z; Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, No. 389, Xincun Road, Shanghai, 200065, China.
Wang S; Medical School of Nantong University, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, Jiangsu, China.
Shan C; Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, No. 389, Xincun Road, Shanghai, 200065, China.
Zhu Q; Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, No. 389, Xincun Road, Shanghai, 200065, China.
Xue Y; Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, No. 389, Xincun Road, Shanghai, 200065, China.
Zhang K; Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, No. 389, Xincun Road, Shanghai, 200065, China. .; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, No. 389, Xincun Road, Shanghai, 200065, China. .
Pokaż więcej
Źródło:
Orphanet journal of rare diseases [Orphanet J Rare Dis] 2023 May 10; Vol. 18 (1), pp. 111. Date of Electronic Publication: 2023 May 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Myositis Ossificans*/genetics
Ossification, Heterotopic*/genetics
Mice ; Animals ; Retrospective Studies ; Mutation ; Bone Morphogenetic Proteins/genetics ; Bone Morphogenetic Proteins/metabolism ; Activin Receptors, Type I/genetics ; Activin Receptors, Type I/metabolism
Czasopismo naukowe
Tytuł:
Transcriptomic Differences Underlying the Activin-A Induced Large Osteoclast Formation in Both Healthy Control and Fibrodysplasia Ossificans Progressiva Osteoclasts.
Autorzy:
Schoenmaker T; Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, 1081 LA Amsterdam, The Netherlands.
Zwaak J; Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, 1081 LA Amsterdam, The Netherlands.
Loos BG; Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, 1081 LA Amsterdam, The Netherlands.
Volckmann R; Center for Experimental and Molecular Medicine, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Koster J; Center for Experimental and Molecular Medicine, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Eekhoff EMW; Department of Internal Medicine Section Endocrinology, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HZ Amsterdam, The Netherlands.; Rare Bone Disease Center Amsterdam, Bone Center, 1081 HV Amsterdam, The Netherlands.
de Vries TJ; Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, 1081 LA Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Apr 06; Vol. 24 (7). Date of Electronic Publication: 2023 Apr 06.
Typ publikacji:
Journal Article
MeSH Terms:
Myositis Ossificans*/genetics
Myositis Ossificans*/metabolism
Ossification, Heterotopic*/genetics
Humans ; Osteoclasts/metabolism ; Transcriptome ; Activins/metabolism ; Mutation ; Activin Receptors, Type I/genetics ; Activin Receptors, Type I/metabolism
Czasopismo naukowe
Tytuł:
Multi-omics therapeutic perspective on ACVR1 gene: from genetic alterations to potential targeting.
Autorzy:
Nagar G
Mittal P
Gupta SRR
Pahuja M
Sanger M
Mishra R
Singh A
Singh IK
Pokaż więcej
Źródło:
Briefings in functional genomics [Brief Funct Genomics] 2023 Apr 13; Vol. 22 (2), pp. 123-142.
Typ publikacji:
Review; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Myositis Ossificans*/genetics
Myositis Ossificans*/drug therapy
Myositis Ossificans*/pathology
Female ; Humans ; Multiomics ; Mutation ; Signal Transduction/genetics ; Activin Receptors, Type I/genetics ; Activin Receptors, Type I/metabolism ; Activin Receptors, Type I/therapeutic use
Czasopismo naukowe
Tytuł:
Upregulation of oncogene Activin A receptor type I by Helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2.
Autorzy:
Chen HY; Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Hu Y; Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Xu XB; Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Zhou YA; Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Li NS; Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
He C; Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Xie C; Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Lu NH; Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Zhu Y; Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Pokaż więcej
Źródło:
Helicobacter [Helicobacter] 2021 Dec; Vol. 26 (6), pp. e12849. Date of Electronic Publication: 2021 Sep 07.
Typ publikacji:
Journal Article
MeSH Terms:
Activin Receptors, Type I*
CDX2 Transcription Factor*/genetics
CDX2 Transcription Factor*/metabolism
Helicobacter Infections*
Helicobacter pylori*/genetics
Helicobacter pylori*/metabolism
Stomach Neoplasms*/genetics
Activins ; Animals ; Gastric Mucosa/metabolism ; Homeodomain Proteins/genetics ; Homeodomain Proteins/metabolism ; Humans ; Metaplasia ; Mice ; Mice, Inbred C57BL ; Oncogenes ; Up-Regulation
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies